TransCode Therapeutics, Inc. (RNAZ)
1.86
+0.15
(+8.77%)
USD |
NASDAQ |
Oct 09, 16:00
1.895
+0.04
(+1.88%)
After-Hours: 20:00
TransCode Therapeutics Max Drawdown (5Y) : 100.00% for Sept. 30, 2026
Max Drawdown (5Y) Chart
Historical Max Drawdown (5Y) Data
| Date | Value |
|---|---|
| September 30, 2026 | 100.00% |
| August 31, 2026 | 100.00% |
| July 31, 2026 | 100.00% |
| June 30, 2026 | 100.00% |
| May 31, 2026 | 100.00% |
| April 30, 2026 | 100.00% |
| March 31, 2026 | 100.00% |
| February 28, 2026 | 100.00% |
| Date | Value |
|---|---|
| January 31, 2026 | 100.00% |
| December 31, 2025 | 100.00% |
| November 30, 2025 | 100.00% |
| October 31, 2025 | 100.00% |
| September 30, 2025 | 100.00% |
| August 31, 2025 | 100.00% |
| July 31, 2025 | 100.00% |
| June 30, 2025 | 100.00% |
Max Drawdown Definition
Max drawdown is an indicator of the risk of a portfolio chosen based on a certain strategy. It measures the largest single drop from peak to bottom in the value of a portfolio before a new peak is achieved.
Max Drawdown (5Y) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Max Drawdown (5Y) Benchmarks
| Arrowhead Pharmaceuticals, Inc. | 88.96% |
| Oncolytics Biotech, Inc. | 92.83% |
| Sangamo Therapeutics, Inc. | 99.68% |
| Sarepta Therapeutics, Inc. | 93.33% |
| Anixa Biosciences, Inc. | 70.17% |
Max Drawdown (5Y) Related Metrics
| Alpha (5Y) | -110.31 |
| Beta (5Y) | 1.249 |
| Annualized Standard Deviation of Monthly Returns (5Y Lookback) | 167.8% |
| Historical Sharpe Ratio (5Y) | -0.5828 |
| Historical Sortino (5Y) | -1.216 |
| Monthly Value at Risk (VaR) 5% (5Y Lookback) | 71.22% |